Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant

Gastroenterology. 2011 Jul;141(1):186-96, 196.e1. doi: 10.1053/j.gastro.2011.04.009. Epub 2011 Apr 16.

Abstract

Background & aims: Immunization against the gastric bacterium Helicobacter pylori could prevent many gastric cancers and other disorders. Most vaccination protocols used in preclinical models are not suitable for humans. New adjuvants and a better understanding of the correlates and requirements for vaccine-induced protection are needed to accelerate development of vaccines for H pylori.

Methods: Vaccine-induced protection against H pylori infection and its local and systemic immunological correlates were assessed in animal models, using cholera toxin or CAF01 as adjuvants. The contribution of B cells, T-helper (Th)-cell subsets, and dendritic cells to H pylori-specific protection were analyzed in mice.

Results: Parenteral administration of a whole-cell sonicate, combined with the mycobacterial cell-wall-derived adjuvant CAF01, protected against infection with H pylori and required cell-mediated, but not humoral, immunity. The vaccine-induced control of H pylori was accompanied by Th1 and Th17 responses in the gastric mucosa and in the gut-draining mesenteric lymph nodes; both Th subsets were required for protective immunity against H pylori. The numbers of memory CD4+ T cells and neutrophils in gastric tissue were identified as the best correlates of protection. Systemic depletion of dendritic cells or regulatory T cells during challenge infection significantly increased protection by overriding immunological tolerance mechanisms activated by live H pylori.

Conclusions: Parenteral immunization with a Helicobacter vaccine using a novel mycobacterial adjuvant induces protective immunity against H pylori that is mediated by Th1 and Th17 cells. Tolerance mechanisms mediated by dendritic cells and regulatory T cells impair H pylori clearance and must be overcome to improve immunity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology*
  • Administration, Intranasal
  • Administration, Oral
  • Animals
  • Antibodies, Bacterial / immunology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • B-Lymphocytes / microbiology
  • Bacterial Vaccines / administration & dosage
  • Bacterial Vaccines / pharmacology*
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / pharmacology*
  • Cell Wall / immunology
  • Chemotaxis / drug effects
  • Cholera Toxin / immunology
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology
  • Dendritic Cells / microbiology
  • Helicobacter Infections / immunology
  • Helicobacter Infections / microbiology
  • Helicobacter Infections / prevention & control*
  • Helicobacter pylori / immunology*
  • Immune Tolerance / drug effects
  • Immunity, Cellular / drug effects
  • Immunity, Humoral / drug effects
  • Injections, Intraperitoneal
  • Injections, Subcutaneous
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Mycobacterium / immunology
  • Stomach / drug effects
  • Stomach / immunology
  • Stomach / microbiology
  • Stomach Neoplasms / immunology
  • Stomach Neoplasms / microbiology
  • Stomach Neoplasms / prevention & control*
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / immunology
  • T-Lymphocytes, Helper-Inducer / microbiology
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / microbiology
  • Time Factors

Substances

  • Adjuvants, Immunologic
  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Cancer Vaccines
  • Cholera Toxin